close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.410 -0.010 (-0.70%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
News headline image
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Participate in December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Lexicon Appoints Ivan H. Cheung to Board of Directors
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Preview: Lexicon Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals ↗
 
Via Benzinga
News headline image
What You Missed On Wall Street This Past Friday ↗
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
News headline image
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Lexicon Pharmaceuticals In The Eyes Of 8 Experts ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 6 Ratings For Lexicon Pharmaceuticals ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results ↗
 
Via Benzinga
News headline image
Dow Jumps 400 Points; US Adds 12,000 Jobs In October ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
5 Analysts Have This To Say About Lexicon Pharmaceuticals ↗
 
Via Benzinga
News headline image
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes ↗
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights ↗
 
Via Benzinga
News headline image
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Intel Reports Weak Results, Joins Amazon, Opendoor Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day ↗
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
News headline image
LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024 ↗
LXRX stock results show that Lexicon Pharmaceuticals met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today